CHMP recommends approval of Enspryng for neuromyelitis optica spectrum disorder – Roche
Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Enspryng (satralizumab) as the first subcutaneous treatment option… read more.